会员体验
专利管家（专利管理）
工作空间（专利管理）
风险监控（情报监控）
数据分析（专利分析）
侵权分析（诉讼无效）
联系我们
交流群
官方交流：
QQ群： 891211   
微信请扫码    >>>
现在联系顾问~
下载
著录项
PDF全文
热词
    • 5. 发明授权
      US07908455B2 Low overhead memory management system and method 有权
    • Low overhead memory management system and method
    • 低开销内存管理系统和方法
    • US07908455B2
    • 2011-03-15
    • US12037943
    • 2008-02-27
    • Michael Palladino
    • Michael Palladino
    • G06F12/00 , G06F13/00 , G06F13/28 , G06F9/26 , G06F9/34
    • G06F12/023
    • A block of contiguous data storage locations of a memory is divided into pools of memory chunks. The memory chunks in same ones of the pools have equal chunk sizes. The memory chunks in different ones of the pools have different chunk sizes. In each of the pools, the memory chunks are addressable by respective chunk base physical addresses in a respective linear contiguous sequence that starts from a respective pool base physical address. The physical addresses of the memory chunks are translated into corresponding internal handles and vice versa, where each of the internal handles is smaller in size than its corresponding physical address. For each of the pools, an associated pool queue comprising respective ones of the internal handles to allocatable ones of the memory chunks in the pool is maintained.
    • 存储器的连续数据存储位置的块被划分为存储块的池。 相同池中的内存块大小相等。 不同池中的内存块具有不同的块大小。 在每个池中，存储器块可由相应的基本物理地址在相应的线性连续序列中寻址，该相应的线性连续序列从相应的池基本物理地址开始。 存储器块的物理地址被转换为对应的内部句柄，反之亦然，其中每个内部句柄的大小小于其对应的物理地址。 对于每个池，维护包括相应的一个内部句柄的关联池队列，以便池中的可分配的一个存储块。
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Espacenet 法律信息 同族专利 专利引用
    • 9. 发明授权
      US07119223B2 Interleukin-1 and tumor necrosis factor-α modulators, synthesis of said modulators and their enantiomers and methods of using said modulators 失效
    • Interleukin-1 and tumor necrosis factor-α modulators, synthesis of said modulators and their enantiomers and methods of using said modulators
    • US07119223B2
    • 2006-10-10
    • US10112681
    • 2002-03-27
    • Michael Palladino , Emmanuel A. Theodorakis
    • Michael Palladino , Emmanuel A. Theodorakis
    • C07C69/74
    • C07C33/14 , A61K31/12 , A61K31/16 , A61K31/215 , C07B2200/05 , C07B2200/07 , C07C57/26 , C07C61/29 , C07C61/35 , C07C62/30 , C07C62/32 , C07C69/753 , C07C69/757 , C07C233/58 , C07C2603/26 , C07D295/15 , C07D295/185 , C07D295/26 , Y02A50/463
    • Novel compounds are disclosed that have the following chemical structures, and prodrug esters and acid-addition salts thereof, that are useful as Interleukin-1 and Tumor Necrosis Factor-α modulators, and thus are useful in the treatment of various diseases. wherein the R groups are defined as follows: if any R3–R5, R7, R8, R11–R13 is not hydrogen, R2 or R6 or R9 is not methyl, or R10 is not CH2, then R1 is selected from the group consisting of hydrogen, a halogen, COOH, C1–C12 carboxylic acids, C1–C12 acyl halides, C1–C12 acyl residues, C1–C12 esters, C1–C12 secondary amides, (C1–C12)(C1–C12) tertiary amides, (C1–C12)(C1–C12) cyclic amides, (C1–C12) amines, C1–C12 alcohols, (C1–C12)(C1–C12) ethers, C1–C12 alkyls, C1–C12 substituted alkyls, C2–C12 alkenyls, C2–C12 substituted alkenyls, and C5–C12 aryls. If all R3–R5, R7, R8, R11–R13 are hydrogen, R2, R6, and R9 are each methyl, and R10 is CH2, then R1 is selected from hydrogen, a halogen, C1–C12 carboxylic acids, C1–C12 acyl halides, C1–C12 acyl residues, C2–C12 esters, C2–C12 secondary amides, (C1–C12)(C1–C12) tertiary amides, C2–C12 alcohols, (C1–C12)(C1–C12) ethers other than methyl-acetyl ether, C2–C12 alkyls, C1–C12 substituted alkyls, C2–C12 alkenyls, C2–C12 substituted alkenyls, and C2–C12 aryls. R2 and R9 are each separately selected from hydrogen, a halogen, C1–C12 alkyl, C1–C12 substituted alkyls, C2–C12 alkenyl, C2–C12 substituted alkenyl, C2–C12 alkynyl, C1–C12 acyl, C1–C12 alcohol, and C5–C12 aryl. R3–R5, R7, R8, and R11–R13 are each separately selected from hydrogen, a halogen, C1–C12 alkyl, C1–C12 substituted alkyls, C2–C12 alkenyl, C2–C12 substituted alkenyl, C2–C12 alkynyl, and C5–C12 aryl. R6 is selected from hydrogen, a halogen, C1–C12 alkyl, C1–C12 substituted alkyls, C2–C12 alkenyl, C2–C12 substituted alkenyl, and C2–C12 alkynyl. R10 is selected from hydrogen, a halogen, CH2, C1–C6 alkyl, C1–C6 substituted alkyl, C2–C6 alkenyl, C2–C6 substituted alkenyl, C1–C12 alcohol, and C5–C12 aryl. Pharmaceutical compositions comprising, and uses of, therapeutically effective amounts of the aove compounds and their prodrug esters, and a pharmaceutically acceptable carrier, are also disclosed, and are useful as, for example, anti-inflammatory analgesics, in treating immune disorders, as anti-cancer and anti-tumor agents, and in the treatment of cardiovascular disease, skin redness, and viral infection. Completely synthetic and semi-synthetic methods of making these compounds and their analogs, are also disclosed.
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Espacenet 法律信息 同族专利 专利引用
每页展示10个专利
每页展示10个专利
每页展示20个专利
每页展示50个专利
每页展示100个专利

IPRDB

最新中国发明专利 最新美国发明专利 技术领域 专利库 专利分类库 国际专利分类库

热门服务

会员版试用 API 数据接口 找代理 知嘟嘟专利交易 排行榜 大学排行榜 专利百科

关于我们

平台介绍 战略合作 网站地图

友情链接

知嘟嘟专利交易 国家知识产权局 中国商标网

联系方式


©2019-2023 上海吉码数字技术有限公司 版权所有，并保留所有权利 沪ICP备20016256号-6 沪公网安备31011702005475号